Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes

NCT ID: NCT00819975

Last Updated: 2009-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enhanced and prolonged postprandial triglyceride responses involve increased cardiovascular risk in type 2 diabetes. It has been demonstrated that dietary fat and carbohydrates profoundly influence postprandial hypertriglyceridemia in type 2 diabetes, whereas little information exists about the effect of proteins.

The purpose of this study is to compare the effects of the milk proteins casein, Whey Isolate, Whey Hydrolysate, and Alphalact-Albumin on postprandial lipid and incretin responses to a high-fat meal in type 2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postprandial Lipemia Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Casein

Group Type ACTIVE_COMPARATOR

Casein

Intervention Type DIETARY_SUPPLEMENT

Whey Isolate

Group Type ACTIVE_COMPARATOR

Whey Isolate

Intervention Type DIETARY_SUPPLEMENT

Whey Hydrolysate

Group Type ACTIVE_COMPARATOR

Whey Hydrolysate

Intervention Type DIETARY_SUPPLEMENT

Alphalact-Albumin

Group Type ACTIVE_COMPARATOR

Alphalact-Albumin

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Casein

Intervention Type DIETARY_SUPPLEMENT

Whey Isolate

Intervention Type DIETARY_SUPPLEMENT

Whey Hydrolysate

Intervention Type DIETARY_SUPPLEMENT

Alphalact-Albumin

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 Diabetes

Exclusion Criteria

* Liver-, Kidney- and/or Heart Disease
* Serious Hypertension (160/110 mmHg)
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Danish Obesity Research Centre

OTHER

Sponsor Role collaborator

Nordic Centre of Excellence

OTHER

Sponsor Role collaborator

Arla Foods

INDUSTRY

Sponsor Role collaborator

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Endocrinology and Metabolism, Aarhus University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kjeld Hermansen, Professor, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Endocrinology and Metabolism

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Nutrition

Aarhus, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CERN-PPL (5B) LSM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Calcium, Protein and Gut Hormones
NCT03232034 COMPLETED NA